Cite
Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.
MLA
Aly, Abdalla, et al. “Survival, Costs, and Health Care Resource Use by Line of Therapy in US Medicare Patients with Newly Diagnosed Glioblastoma: A Retrospective Observational Study.” Neuro-Oncology Practice, vol. 7, no. 2, Apr. 2020, pp. 164–75. EBSCOhost, https://doi.org/10.1093/nop/npz042.
APA
Aly, A., Singh, P., Korytowsky, B., Ling, Y.-L., Kale, H. P., Dastani, H. B., Botteman, M. F., & Norden, A. D. (2020). Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. Neuro-Oncology Practice, 7(2), 164–175. https://doi.org/10.1093/nop/npz042
Chicago
Aly, Abdalla, Prianka Singh, Beata Korytowsky, You-Li Ling, Hrishikesh P Kale, Homa B Dastani, Marc F Botteman, and Andrew D Norden. 2020. “Survival, Costs, and Health Care Resource Use by Line of Therapy in US Medicare Patients with Newly Diagnosed Glioblastoma: A Retrospective Observational Study.” Neuro-Oncology Practice 7 (2): 164–75. doi:10.1093/nop/npz042.